Evaluation And Invivo Studies of Solid Lipid Nano Carrier Mediated Drug Delivery System of Perinodopril

Main Article Content

Mahesh, Pg., Somasundaram, I.

Abstract

High BP is one of the most predominant causes of heart diseases and cerebrovascular problems. Perinodopril is an ACE inhibitor that is a non sulfhydryl derivative that is used for the treatment of hypertension. To enhance the effect of the drug it was formulated into Lipid based nano carrier system (NLC) to improve the bioavailability and thereby the therapeutic potential. So the objective of the current work was to evaluate the NLC of perinodopril formulation and to evaluate the same. The invivo estimation of the activity was carried out on Albino wistar rats that are maintained under room conditions and the formulation was investigated for the Pharamcokinetic and pharmacodynamic paramteres in rat plasma. Also they were tested for their stability invitro. Results show that the nano particles measured as 0.207nm in size. The invitro drug release studies suggest that the formulations were releasing the drug in controlled fashion during 23 hrs. stability studies proves the drug is very stable in the formulation. With R2 = 0.9683, the in vitro-in vivo correlation research clearly shows good agreement between in vitro drug solubilization during lipolysis and in vivo drug absorption during pharmacokinetic studies. This in vitro lipolysis research, which has an R2 close to 1, suggests that this model can match the in vivo dissolution profile in the gut.

Article Details

Section
Articles